Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00174252
Status:
COMPLETED
Last Update Posted:
2010-06-15
First Post:
2005-09-09
Brief Title:
Study Aimed At Improving Height With Genotonorm In Children Born Little AndOr Light With Growth Retardation At The Age
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Evolution of IGF-1 in Children Born Small for Gestational Age and With Growth Retardation Treated by Genotonorm Especially Evolution After Dose Adaptation
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To estimate the percentage of children with serum IGF-1 2 standard deviation compared to a child of the same gender and age and without growth hormone GH deficiency 9 months and 12 months after initiation of GH treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None